Generali Investments CEE investicni spolecnost a.s. Makes New $243,000 Investment in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Generali Investments CEE investicni spolecnost a.s. purchased a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 2,000 shares of the biotechnology company’s stock, valued at approximately $243,000.

Several other institutional investors have also recently made changes to their positions in the stock. Manchester Capital Management LLC increased its holdings in shares of Sarepta Therapeutics by 86.6% during the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 110 shares during the last quarter. MassMutual Private Wealth & Trust FSB increased its holdings in shares of Sarepta Therapeutics by 169.6% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 156 shares during the last quarter. Sunbelt Securities Inc. increased its holdings in shares of Sarepta Therapeutics by 446.2% during the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 232 shares during the last quarter. Huntington National Bank increased its holdings in shares of Sarepta Therapeutics by 150.9% during the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 175 shares during the last quarter. Finally, Newbridge Financial Services Group Inc. acquired a new position in shares of Sarepta Therapeutics during the 4th quarter worth approximately $36,000. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Price Performance

Shares of SRPT stock opened at $103.03 on Monday. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a twelve month low of $99.50 and a twelve month high of $173.25. The company has a market cap of $10.00 billion, a P/E ratio of 82.42 and a beta of 0.79. The business has a fifty day simple moving average of $114.11 and a 200 day simple moving average of $121.27.

Insider Buying and Selling

In related news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the company’s stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the sale, the director now directly owns 22,840 shares in the company, valued at $2,851,345.60. This represents a 31.49 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 7.70% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on SRPT shares. Deutsche Bank Aktiengesellschaft started coverage on Sarepta Therapeutics in a report on Tuesday, February 11th. They set a “hold” rating and a $136.00 target price on the stock. HC Wainwright reissued a “sell” rating and set a $75.00 target price on shares of Sarepta Therapeutics in a report on Thursday, February 27th. Royal Bank of Canada decreased their price objective on Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating on the stock in a report on Thursday, February 27th. Scotiabank began coverage on Sarepta Therapeutics in a report on Friday. They issued a “sector perform” rating and a $105.00 price objective on the stock. Finally, StockNews.com lowered Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $170.41.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.